J&J Wins FDA Approval for Icotyde — First Oral IL-23 Pill for Psoriasis
By FieldPulse Staff · March 18, 2026
Tags: launch, strategy, field
J&J's once-daily psoriasis pill Icotyde approved March 18 — the first oral IL-23 inhibitor. J&J eyes $5B+ peak sales. AbbVie's Skyrizi and J&J's own Tremfya now face oral competition.
Johnson & Johnson received FDA approval on March 18, 2026 for Icotyde (icotrokinra), making it the first oral IL-23 inhibitor cleared for moderate-to-severe plaque psoriasis in patients aged 12 and older.
The once-daily pill enters a market dominated by injectable biologics, including AbbVie's Skyrizi (risankizumab) and J&J's own Tremfya (guselkumab) — both subcutaneous injections.
J&J projects peak annual sales exceeding $5 billion, positioning Icotyde as a major growth driver for its immunology franchise.
The approval creates a significant new competitive dynamic in dermatology: for the first time, reps can offer a targeted biologic-class mechanism in an oral format.
AbbVie's Skyrizi team, which had held strong on efficacy data against all comers, now faces a convenience-driven counter-narrative.
Meanwhile, J&J faces its own internal positioning challenge — Tremfya remains on formulary and in widespread use, and the field force will need a clear segmentation story to avoid cannibalization.